Skip to Content
Merck
All Photos(1)

Documents

Z-003

Supelco

Zopiclone solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H17ClN6O3
CAS Number:
43200-80-2
Molecular Weight:
388.81
EC Number:
200-835-2
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

C[NH+]1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4

InChI

1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/p+1

InChI key

GBBSUAFBMRNDJC-UHFFFAOYSA-O

Related Categories

General description

A certified solution standard suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, pharmaceutical research, or urine drug testing.  Zopiclone is a non-benzodiazepine hypnotic sold under the trade names Imovane® and ZImovane® and is prescribed for the treatment of insomnia.

Application

  • Zopiclone solution pharmacological research applications: Utilized in developing and validating analytical methods for detecting z-drugs in biological samples, enhancing forensic toxicology and clinical diagnostics (Chauhan et al., 2024).
  • Zopiclone as a GABA receptor modulator in biochemistry: Investigated for its role in drug-facilitated crimes, particularly its identification through presumptive spot tests, which is crucial for forensic analysis (Chauhan and Sharma, 2023).
  • Zopiclone solution for sleep disorder experimental studies: Analyzed for its effects on hyperlipidemic conditions in postmortem blood, contributing to forensic science and medical research (Elenstål et al., 2023).
  • Zopiclone liquid formulation stability in laboratory conditions: Reviewed for long-term medication use in insomnia treatments, providing essential data on clinical safety and efficacy (Zee et al., 2023).
  • Zopiclone in vitro receptor binding assays methodology: Employed in evaluating the toxicity of zopiclone impurities, supporting the development of safer pharmaceutical products (Yin et al., 2023).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Imovane is a registered trademark of Sanofi-Aventis
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alan Wayne Jones et al.
Forensic science international, 222(1-3), 118-123 (2012-06-08)
The concentrations of zolpidem and zopiclone were determined in peripheral blood samples in two forensic materials collected over a 10-year period (2001-2010). The z-hypnotics were determined in venous blood from living subjects (impaired drivers) and in femoral blood from deceased
Julia Boyle et al.
Journal of clinical psychopharmacology, 32(5), 704-709 (2012-08-29)
Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During
Coma after single dose of zopiclone.
Annelie K Hintzen et al.
The American journal on addictions, 21(3), 291-291 (2012-04-13)
To breathe, perchance not to wake?
David M Rapoport
Journal of applied physiology (Bethesda, Md. : 1985), 112(2), 247-248 (2011-10-29)
Nico J Diederich et al.
Journal of the neurological sciences, 314(1-2), 12-19 (2011-11-29)
Sleep symptoms in Parkinson's disease (PD) are frequent and have multifactorial and multilayered causes. Primary involvement of sleep/wake regulating centers in the brainstem, sleep problems caused by the nocturnal manifestation of motor and dysautonomic signs and medication-induced sleep problems are
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service